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Abstract
It has been suggested that a common LRRK2 polymorphic variant (A419V (rs34594498 C .T)) may be a risk factor among
Asians (especially in Taiwan). In this study, we examined this variant in a larger and independent Taiwan cohort. We found
the frequency of the variant (A419V) to be very rare in our Taiwan PD and controls (?0.6%). Further studies were conducted
in two other Chinese populations (Singapore and China), comprising of a total of 3004 subjects including 1517 PD patients
and 1487 control subjects. However, our multi-center Chinese study revealed that the frequency of the variant was rare
(?0.4%) and was not associated with risk of PD, suggesting that the variant is not a major risk factor for PD among Chinese,
at least in our study population.
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Introduction
Several pathogenic genes and susceptibility loci of Parkinson’s
disease (PD) have been identified in both familial and sporadic
cases in the last decade [1]. Mutations in the leucine-rich repeat
kinase 2 gene (LRRK2/PARK8) were reported as a cause of PD in
families with an autosomal dominant pattern of inheritance by two
groups in 2004 [2,3]. There has been considerable interest in
LRRK2, probably due to the discovery of a common mutation
(G2019S) [4] in many countries and its high frequency (30–40%)
among Ashkenazi Jews and north African Arabs as well as the
discovery of common risk variants (G2385R and R1268P) among
Asians [5,6].
Recently, investigators in a multi-center study genotyped 121
exonic LRRK2 variants in three ethnic series (white, Asian, and
Arab–Berber), and identified a common polymorphic risk variant
(A419V (rs34594498 C .T)) in 3 Asian cohorts (1376 Asian
patients and 962 controls) [7]. Remarkably, the variant A419V
conferred an increased risk in developing PD with an odds ratio of
.7.0 in one cohort consisting of ethnic Chinese from Taiwan [7].
Currently, it is unclear whether this observation is specific to
ethnic Chinese or this risk factor applies to Asians in general.
Results
The mean age at onset of PD in the three groups (Taiwan,
Singapore and China) was 63.0611.2, 64610, 60.1611.0 years,
and the mean age of control subjects at recruitment was
60.1611.2, 59.969.8 and 60.2613.2 years. The gender of the
patient and control groups was matched in each cohort. All three
cohorts showed similar minor allele frequency (MAF) of the SNP
in the normal population (the frequency of 200 cases in Singapore
was previously reported to be 0.4%) [8], but a marginal higher
MAF was found in the PD group of the China cohort (Table 1).
Discussion
Our multi-center Chinese study, with a much larger sample size
(.3000) than the previously reported Taiwan Chinese cohort
(about 700) or combined mixed Asian cohort (.2300), showed the
frequency of the variant was rare (?0.4%) and was not associated
with risk of PD, suggesting that the variant is not a major risk
factor for PD among Chinese, at least in our study population.
It’s intriguing why the results of ours and the other Taiwanese
group in the multi-center study were markedly different [7].
Possible reasons may be due to very low MAF (0.33–1.9%) of the
exonic variant (A419V), natural sampling variation, and popula-
tion heterogeneity. The potential biological functions for this SNP
are unknown. A419V is near the N-terminal region of the LRRK2
protein and maybe functionally relevant to disease development,
or it is in linkage disequilibrium with a non coding variant or the
actual causative variant. As new loci susceptible to different
complex diseases are continuously being discovered in genome-
wide association and whole-genome sequencing studies, the results
of our study demonstrate the importance of revisiting loci at which
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common or rare variants have been identified. It is possible that
the A419V variant is a risk factor in only selected Asian
populations or even subset of Chinese, unlike G2385R which
has been consistently seen across all Chinese populations [5].
Other factors such as gene-gene, gene-environmental factors may
be confounding variables to explain the divergent associations
observed. Further multi-center studies will be warranted to
characterize the frequency of the variant in different populations,




All subjects gave written informed consent for this study under a
protocol approved by local hospital internal ethics and scientific
boards. (Chang Gung Memorial Hospital internal ethics and
scientific boards for the Taiwanese cohort, Singapore General
Hospital and Singhealth ethics and scientific boards for the
Singapore cohort and The First Affiliated Hospital internal ethics
and scientific boards, Sun Yat-Sen University for the China
cohort).
Subjects
The diagnosis of PD was based on the UK PD Society Brain
Bank clinical diagnostic criteria (more than one affected relative
was excluded). Unrelated healthy adult volunteers matched for
age, gender, ethnic origin, and area of residences were recruited as
controls. We first recruited 485 PD patients and 494 control
subjects in the Taiwanese Cohort and we found the frequency of
the variant (A419V) to be very rare (,0.6%). The subjects
examined here did not overlap with the Taiwanese population
included in the study performed by Ross et al [7]. Therefore,
additional replications were conducted in two other Chinese
population (Singapore and China), comprising of a total of 3004
subjects including 1517 PD patients and 1487 control subjects
subsequently to be analyzed.
Genotyping
TaqManH Assays were used for SNP genotyping analysis in the
Taiwanese cohort. Genotyping was carried out with mass
spectrometric analysis using the SequanomR and sequence analysis
from Singapore, and direct sequence analysis in the China cohort.
Statistical Analyses
Chi square test was used to compare the frequency of the allele
in both cases and controls. The genotypes of the case and controls
followed the Hardy Weinberg equilibrium. Odds ratios and 95%
confidence intervals were estimated. A free and open source
software (OpenEpi) was used for the statistical analysis [9].
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